Ironwood Pharmaceuticals, Inc. provided earnings guidance for the full year 2023. For the year, the company expects total revenue to be in the range of $420 million to $435 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.82 USD | -0.87% | +5.57% | -40.38% |
07-01 | Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Value-Defensive Index | CI |
07-01 | Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) added to Russell 2000 Dynamic Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.38% | 1.08B | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+43.96% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- IRWD Stock
- News Ironwood Pharmaceuticals, Inc.
- Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023